Journal: Cancers

Article Title: Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer

doi: 10.3390/cancers14143513

Figure Lengend Snippet: Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in MDA-MB-231 cells. MDA-MB-231 cells (MDA) were stimulated by TNFα (0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ) and CXCL1 ( B ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05. # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Article Snippet: To determine the impact of recombinant soluble (rs) TNFR1 and rsTNFR2 on induction of TNFα-induced chemokine production, rsTNFR1 (150 ng/mL, #636-R1, R&D Systems), rsTNFR2 (500 ng/mL, #1089-R2, R&D Systems), both of them together or a vehicle control were incubated with TNFα (0.5 ng/mL, #300-01A, PeproTech) for 60 min at room temperature.

Techniques: Recombinant, Derivative Assay, Expressing, Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Cancers

Article Title: Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer

doi: 10.3390/cancers14143513

Figure Lengend Snippet: Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in BT-549 cells. BT-549 cells (BT) were stimulated by TNFα (0.25–0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ), CXCL1 ( B ) and CCL5 ( C ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05, # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Article Snippet: To determine the impact of recombinant soluble (rs) TNFR1 and rsTNFR2 on induction of TNFα-induced chemokine production, rsTNFR1 (150 ng/mL, #636-R1, R&D Systems), rsTNFR2 (500 ng/mL, #1089-R2, R&D Systems), both of them together or a vehicle control were incubated with TNFα (0.5 ng/mL, #300-01A, PeproTech) for 60 min at room temperature.

Techniques: Recombinant, Derivative Assay, Expressing, Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: In vitro physical and functional interaction assays to examine the binding of progranulin derivative Atsttrin to TNFR2 and its anti-TNFα activity

doi: 10.1007/978-1-0716-1130-2_8

Figure Lengend Snippet: (a) Binding of Atsttrin to TNFR2. (b) Atsttrin inhibition of TNFα binding to TNFR2.

Article Snippet: Recombinant proteins: Recombinant Atsttrin (Atreaon, Inc), Recombinant Human TNFR2, (R&D Systems, carrier free), Recombinant Human TNFα (R&D Systems, carrier free).

Techniques: Binding Assay, Inhibition

Journal: Cancer

Article Title: Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

doi: 10.1002/cncr.30845

Figure Lengend Snippet: Figure 3. Kaplan-Meier curves illustrate progression-free sur- vival in subgroups of patients with (A) low and (B) high baseline levels of tumor necrosis factor receptor II (TNFR II).

Article Snippet: Assays for serum TNFR II were conducted using an enzyme-linked immunosorbent assay with a commercially available human TNFR II/TNFRSF 1B Immunoassay (R&D Systems, Minneapolis, MN) according to the manufacturer’s recommendations.

Techniques: